现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
24期
3654-3657
,共4页
王存邦%白海%葸瑞%潘耀柱%徐淑芬%张茜%陈燕%周进茂%吴涛
王存邦%白海%葸瑞%潘耀柱%徐淑芬%張茜%陳燕%週進茂%吳濤
왕존방%백해%사서%반요주%서숙분%장천%진연%주진무%오도
非霍奇金淋巴瘤%B 细胞性%自体外周血干细胞移植%过继免疫治疗%疗效
非霍奇金淋巴瘤%B 細胞性%自體外週血榦細胞移植%過繼免疫治療%療效
비곽기금림파류%B 세포성%자체외주혈간세포이식%과계면역치료%료효
non -Hodgkin's lymphoma%B lymphocyte%autologous peripheral blood stem cell transplantation%adop-tive immunotherapy%efficacy
目的:探讨自体外周血干细胞移植联合过继免疫治疗 B 细胞性非霍奇金淋巴瘤(non -Hodgkin's lymphoma,NHL)的疗效。方法:以2000年1月-2009年12月经病理形态学及免疫组织化学检查确诊的78例 B 细胞性 NHL 患者为治疗组,交替应用 CHOP、TAOP 和 MEOP 方案各2个疗程化疗后,以化疗联合重组人粒细胞集落刺激因子方法动员自体外周血干细胞,TBI +VEMAC 方案实施预处理,进行自体外周血干细胞移植。造血恢复后每月给予重组人白细胞介素-2100WU /d ×10天为1个疗程的过继免疫治疗,6个疗程后观察疗效。以1995年1月-1999年12月的52例 B 细胞性 NHL 患者为对照组,化疗及移植方法同上,未给予过继免疫治疗。随访时间5年。结果:治疗组及对照组中各有1例患者在3个月、2个月时分别因肝功衰竭和脑出血死亡,其他患者均获得造血重建。随访1年时,治疗组和观察组患者无病生存(disease free survival, DFS)率分别为96.2%、90.4%(P >0.05)。随访3、5年时,两组患者的 DFS 分别为93.6%、88.5%和73.1%、65.4%(P <0.01)。随访1年时,两组中 III /IV 期患者的 DFS 分别为95.2%和88.1%(P >0.05)。随访3、5年时,两组中 III /IV 期患者的 DFS 分别为92.1%、87.3%和69.0%、59.5%(P <0.01)。结论:自体外周血干细胞移植联合过继免疫治疗 B 细胞性 NHL 疗效显著,尤其 III /VI 期患者获益明显。
目的:探討自體外週血榦細胞移植聯閤過繼免疫治療 B 細胞性非霍奇金淋巴瘤(non -Hodgkin's lymphoma,NHL)的療效。方法:以2000年1月-2009年12月經病理形態學及免疫組織化學檢查確診的78例 B 細胞性 NHL 患者為治療組,交替應用 CHOP、TAOP 和 MEOP 方案各2箇療程化療後,以化療聯閤重組人粒細胞集落刺激因子方法動員自體外週血榦細胞,TBI +VEMAC 方案實施預處理,進行自體外週血榦細胞移植。造血恢複後每月給予重組人白細胞介素-2100WU /d ×10天為1箇療程的過繼免疫治療,6箇療程後觀察療效。以1995年1月-1999年12月的52例 B 細胞性 NHL 患者為對照組,化療及移植方法同上,未給予過繼免疫治療。隨訪時間5年。結果:治療組及對照組中各有1例患者在3箇月、2箇月時分彆因肝功衰竭和腦齣血死亡,其他患者均穫得造血重建。隨訪1年時,治療組和觀察組患者無病生存(disease free survival, DFS)率分彆為96.2%、90.4%(P >0.05)。隨訪3、5年時,兩組患者的 DFS 分彆為93.6%、88.5%和73.1%、65.4%(P <0.01)。隨訪1年時,兩組中 III /IV 期患者的 DFS 分彆為95.2%和88.1%(P >0.05)。隨訪3、5年時,兩組中 III /IV 期患者的 DFS 分彆為92.1%、87.3%和69.0%、59.5%(P <0.01)。結論:自體外週血榦細胞移植聯閤過繼免疫治療 B 細胞性 NHL 療效顯著,尤其 III /VI 期患者穫益明顯。
목적:탐토자체외주혈간세포이식연합과계면역치료 B 세포성비곽기금림파류(non -Hodgkin's lymphoma,NHL)적료효。방법:이2000년1월-2009년12월경병리형태학급면역조직화학검사학진적78례 B 세포성 NHL 환자위치료조,교체응용 CHOP、TAOP 화 MEOP 방안각2개료정화료후,이화료연합중조인립세포집락자격인자방법동원자체외주혈간세포,TBI +VEMAC 방안실시예처리,진행자체외주혈간세포이식。조혈회복후매월급여중조인백세포개소-2100WU /d ×10천위1개료정적과계면역치료,6개료정후관찰료효。이1995년1월-1999년12월적52례 B 세포성 NHL 환자위대조조,화료급이식방법동상,미급여과계면역치료。수방시간5년。결과:치료조급대조조중각유1례환자재3개월、2개월시분별인간공쇠갈화뇌출혈사망,기타환자균획득조혈중건。수방1년시,치료조화관찰조환자무병생존(disease free survival, DFS)솔분별위96.2%、90.4%(P >0.05)。수방3、5년시,량조환자적 DFS 분별위93.6%、88.5%화73.1%、65.4%(P <0.01)。수방1년시,량조중 III /IV 기환자적 DFS 분별위95.2%화88.1%(P >0.05)。수방3、5년시,량조중 III /IV 기환자적 DFS 분별위92.1%、87.3%화69.0%、59.5%(P <0.01)。결론:자체외주혈간세포이식연합과계면역치료 B 세포성 NHL 료효현저,우기 III /VI 기환자획익명현。
Objective:To investigate the efficacy treated with autologous peripheral blood stem cell transplantation (APBSCT)combined adoptive immunotherapy in non -Hodgkin's lymphoma(NHL)of B lymphocyte.Methods:A to-tal 78 patients diagnosed as NHL of B lymphocyte by pathology and immunohistochemistry from January 2000 to De-cember 2009,as treatment group,were treated sequentially with chemotherapy regimens(CHOP,TAOP,MEOP)for 2 courses respectively.After that,autologous peripheral blood stem cells were mobilized with chemotherapy combined rhG -CSF,and received APBSCT after conditioning regimen with TBI combined VEMAC.After hematopoietic recon-struction,they were given six courses of adoptive immunotherapy(rhIL -2 100WU /day for 10 days monthly for each course).52 cases of NHL patients of B lymphocyte from January 1995 to December 1999,as control group,received chemotherapy regimens and APBSCT only,but no rhIL -2 adoptive immunotherapy.All patients were followed -up for more than 5 years.Results:There was one patient in each group,who died of liver failure and cerebral hemorrhage respectively within three and two months,and other patients achieved hematopoietic reconstruction.Follow -up 1 year,disease free survival(DFS)rates were 96.2% and 90.4% respectively(P >0.05).Follow -up 3 and 5 years, DFS rates were 93.6%,88.5% and 73.1%,65.4% respectively(P <0.01).Follow -up of 1 year,DFS rates in phase III /IV of two groups were 95.2% and 88.1%(P >0.05).Follow -up of 3 and 5 year,DFS rates in phase III /IV of two groups were 92.1%,87.3% and 69.0%,59.5% respectively(P <0.01).Conclusion:There were obvious efficacy to patients of NHL of B lymphocyte treated with APBSCT combined adoptive immunotherapy,especially to pa-tients with phase III /IV.